- In May 2023, WellSky, a prominent technology company in health and community care, has unveiled new predictive analytics features in its CarePort Connect solution. These enhancements aim to assist hospitals, payers, and post-acute care providers in more effectively identifying patients who are appropriate for hospice care and facilitating timely referrals. With a referral network encompassing 2,000 hospitals across the U.S., WellSky facilitates over 13 million hospital discharges annually and is now launching a groundbreaking national hospice suitability identification network
- In May 2024, Premier, Inc. is pleased to announce a strategic partnership with AstraZeneca for the Uncover CKD - Care Collective initiative. This collaboration aims to identify patients with undiagnosed clinical chronic kidney disease (CKD), enhance awareness of undiagnosed CKD among healthcare providers, and guide U.S. health systems looking to improve or establish strategies for the diagnosis, treatment, and management of CKD
- In Januray 2024, Eli Lilly and Company has announced the launch of LillyDirect, a new digital healthcare platform designed for patients in the U.S. dealing with obesity, migraine, and diabetes. LillyDirect provides disease management resources, including access to independent healthcare providers, personalized support, and the direct home delivery of select Lilly medications via third-party pharmacy dispensing services
- In November 2021, IBM introduced Imaging AI Orchestration, a groundbreaking solution designed to enable imaging organizations to harness the full potential of artificial intelligence applications in a cohesive manner. This platform allows for the seamless integration of various AI tools, enhancing workflow efficiency and improving diagnostic accuracy in medical imaging
- In April 2021, WellSky introduced an advanced management solution for home health visits called CareInsights Guidance. This innovative component provides actionable insights on visit utilization, aimed at optimizing treatment quality and enhancing patient health outcomes. The launch of this solution is anticipated to benefit both patients and employees while driving the company's sales growth
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Solution and Services), Disease Indication (Cardiovascular Diseases (CVD), Diabetes, Chronic Obstructive Pulmonary Disorders (COPD), Arthritis, Asthma, Cancer, and Others), Deployment Types (On-premises, Cloud-based, and Web-based), End User (Healthcare Providers, Healthcare Payers, and Others) – Industry Trends and Forecast to 2031
.
The Global Chronic Disease Management Market size was valued at USD 7.17 USD Billion in 2023.
The Global Chronic Disease Management Market is projected to grow at a CAGR of 16.3% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
